Mary K Olson

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. ncbi The risk we bear: the effects of review speed and industry user fees on new drug safety
    Mary K Olson
    Department of Economics, Tulane University, 6823 St Charles Avenue, New Orleans, LA 70118 5698, USA
    J Health Econ 27:175-200. 2008
  2. ncbi Managing delegation in the FDA: reducing delay in new-drug review
    Mary K Olson
    Yale University, USA
    J Health Polit Policy Law 29:397-430. 2004
  3. ncbi Explaining reductions in FDA drug review times: PDUFA matters
    Mary K Olson
    Yale University, New Haven, Connecticut, USA
    Health Aff (Millwood) . 2003
  4. ncbi Are novel drugs more risky for patients than less novel drugs?
    Mary K Olson
    School of Public Health, Yale University, New Haven, CT 06520, USA
    J Health Econ 23:1135-58. 2004

Detail Information

Publications4

  1. ncbi The risk we bear: the effects of review speed and industry user fees on new drug safety
    Mary K Olson
    Department of Economics, Tulane University, 6823 St Charles Avenue, New Orleans, LA 70118 5698, USA
    J Health Econ 27:175-200. 2008
    ..Although any increase in risks must be weighed against benefits, the results show a trade-off between review speed and drug safety...
  2. ncbi Managing delegation in the FDA: reducing delay in new-drug review
    Mary K Olson
    Yale University, USA
    J Health Polit Policy Law 29:397-430. 2004
    ..The results suggest that the user fee reform has helped politicians manage delegation and reduce delay in new-drug review...
  3. ncbi Explaining reductions in FDA drug review times: PDUFA matters
    Mary K Olson
    Yale University, New Haven, Connecticut, USA
    Health Aff (Millwood) . 2003
    ..She also found that there was little reduction in drug review times until after user fees were introduced...
  4. ncbi Are novel drugs more risky for patients than less novel drugs?
    Mary K Olson
    School of Public Health, Yale University, New Haven, CT 06520, USA
    J Health Econ 23:1135-58. 2004
    ..These results suggest that novel drugs pose greater risk of serious ADRs for patients relative to less novel drugs...